Scandinavian ChemoTech has been invited to participate in both the Life Science Intelligence "LSI" Emerging Medtech Summit in California and the EU Gateway - Business Avenues in Singapore and Indonesia.

LSI Emerging Medtech Summit is an event that brings together the best strategists, investors and innovators in the Med Tech industry. The summit will take place at the Ritz - Carlton in Laguna Niguel California on February 17 - 20, 2021 and is a 3-day event where ChemoTech and other medical technology companies will present their innovations to some of the largest medical technology players and institutional investors. ChemoTech was also invited to the event in 2020 but could unfortunately not participate.

The company has also been selected for an EU-led export delegation to Singapore and Indonesia, which is largely funded by the EU. The delegation takes place in connection with one of Asia's largest medical technology fairs 9 - 11 December 2020, which takes place in Singapore. After Singapore, the delegation will continue to a medical technology fair in Jakarta, Indonesia, with the opportunity to continue to showcase the company's products to doctors, veterinarians and industry stakeholders, as well as to establish contacts with strategic partners.

"We feel honoured to have been selected to present our company and patented technology at these prestigious events. We look forward to reaching a wider audience with our tumour specific electroporation and making new business contacts for both veterinary and human medicine. We are of course prepared that these events, due to prevailing pandemic, may be cancelled or postponed. "- says Mohan Frick, CEO

For further information please contact:

Mohan Frick, Co-Founder and CEO

+46 (0)10-218 93 00

[email protected]


Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: [email protected]

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumour specific electroporation, available for treatment of both for humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where tumour specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at:,c3180691

(c) 2020 Cision. All rights reserved., source Press Releases - English

Source link